IMRX — Immuneering Cashflow Statement
0.000.00%
Last trade - 00:00- $32.92m
- -$38.36m
- 21
- 49
- 14
- 18
Annual cashflow statement for Immuneering, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -7.71 | -17 | -33.5 | -50.5 | -53.5 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 2.81 | 1.14 | 2.05 | 4.42 | 5.13 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.437 | 1.25 | 0.9 | 1.72 | -0.975 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -4.44 | -14.6 | -30.9 | -44.1 | -49 |
| Capital Expenditures | -0.021 | -0.053 | -0.061 | -0.742 | -0.343 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | -75.6 | 42.6 | 7.64 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.021 | -0.053 | -75.6 | 41.8 | 7.3 |
| Financing Cash Flow Items | -0.056 | 0 | -2.12 | -0.281 | -0.204 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 17.2 | 38 | 144 | 0.019 | 28.4 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 12.7 | 23.3 | 37.8 | -2.25 | -13.2 |